Some links on this page are affiliate links: if you buy through them we may earn a commission, at no extra cost to you.
For most drug-discovery enzyme programs, start with directed evolution when you already have a functional scaffold, a validated assay and enough screening capacity. Add AI design when screening is the bottleneck, when sequence or structure data can support prediction, or when you need to search beyond close natural homologues. In practice, a hybrid design-build-test-learn loop is usually the most defensible plan: computational models focus the library, while experimental evolution and biochemical testing decide what works under your actual assay conditions.
Neither method removes the central requirement of enzyme discovery: measuring real molecules in the intended assay and then checking selectivity, stability, expression and developability. AI can propose or rank sequences, but a plausible fold is not proof of catalysis. Directed evolution can improve a measurable phenotype, but it may require testing thousands of variants and can remain trapped near the starting scaffold.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Lippincott® Illustrated Reviews: Biochemistry (Lippincott Illustrated Reviews Series) | $75.48 | Buy on Amazon |
| 2 |
|
Lehninger Principles of Biochemistry | $363.98 | Buy on Amazon |
| 3 |
|
Biochemistry For Dummies | $23.92 | Buy on Amazon |
| 4 |
|
Biochemistry | $107.51 | Buy on Amazon |
| 5 |
|
Textbook of Biochemistry with Clinical Correlations | $116.46 | Buy on Amazon |
As an Amazon Associate I earn from qualifying purchases.
What the two approaches actually do
AI-designed enzymes
AI design covers several different activities rather than one laboratory protocol. A model may generate new sequences, rank mutations in an existing enzyme, identify distant homologues, or use a predicted structure to suggest active-site and stability changes. The common feature is that much of the search happens in silico before DNA is ordered.
The practical output is usually a tractable set of candidates: for example, a focused library selected from many computational proposals. That can reduce synthesis and screening burden, particularly when a project has curated sequence data, a reliable structure or structural model, and assay results that can be used for ranking. The model does not establish catalytic turnover, substrate selectivity, expression, solubility, manufacturability or pharmacological suitability. Those properties still require experiments.
#1 Best Overall
Directed evolution
Directed evolution starts with an enzyme that already performs a measurable function. Researchers create genetic diversity through mutagenesis, recombination or targeted changes, then select or screen variants under conditions chosen to represent the desired phenotype. The best performers become parents for subsequent rounds.
Because the selection is tied to an observed phenotype, directed evolution can optimize activity, selectivity, stability, expression or tolerance to solvent and pH without requiring a complete mechanistic model. Its cost is experimental scale. A Protein Science review describes directed-evolution approaches as often requiring experimental testing of thousands of variants. If the assay is slow, noisy or poorly correlated with the drug-discovery objective, that throughput requirement becomes the program’s main constraint.
Free tools Windows power users keep installed
One-click scans. No signup required.
AI design versus directed evolution at a glance
| Decision axis | AI design | Directed evolution |
|---|---|---|
| Starting information | Benefits from curated sequences, structures, assay data or a combination of them. | Needs a functional starting scaffold and a measurable phenotype; complete structural knowledge is optional. |
| Search strategy | Generates or ranks sequences computationally, then tests a selected subset. | Samples experimentally through mutation, recombination and selection or screening. |
| Typical library burden | Can focus synthesis on a smaller, model-prioritized set, although every candidate still needs testing. | May require screening thousands of variants, depending on library design and assay throughput. |
| Sequence novelty | Can explore distant homologues and de novo sequences beyond close natural neighbors. | Usually searches locally around an existing scaffold, unless broad diversity is deliberately introduced. |
| Assay dependence | Assays are required to validate predictions and train or update models; prediction alone is insufficient. | A robust selectable or screenable phenotype is essential from the first round. |
| Main technical risks | Model bias, out-of-distribution sequences, inaccurate ranking and plausible-looking but inactive proteins. | Epistasis, incomplete library coverage, false positives and a screening bottleneck. |
| Best decision endpoint | Not merely a high model score: experimentally confirmed activity plus selectivity, stability, expression and developability. | Not merely enrichment or a single activity reading: the same multidimensional developability panel. |
The methods are therefore complementary. AI changes which molecules enter the laboratory; directed evolution changes molecules by repeatedly measuring their performance. A comparison that ignores the assay, library size, endpoint definition and enzyme class cannot produce a reliable universal winner.
When directed evolution should come first
Choose an evolution-first plan when the following conditions are substantially true:
Rank #2
- You have a validated high-throughput assay or selection. The readout should correlate with the activity that matters in the drug-discovery program, not merely with an easy surrogate.
- Your starting enzyme already acts on the relevant substrate. Even modest measurable activity gives each round a phenotype to improve.
- The objective is optimization around an existing fold. Directed evolution is well suited to improving catalytic activity, selectivity, thermal or chemical stability, expression, solubility, solvent tolerance or pH tolerance.
- You can build and screen the required library. Confirm that cloning, expression, purification or whole-cell handling and data analysis can sustain the planned number of variants.
- The program values demonstrated function over sequence novelty. If the target is a better version of a known scaffold, local experimental search may have a lower validation risk than de novo generation.
Evolution is particularly attractive when the assay is fast and inexpensive relative to DNA construction. Each round supplies new, project-specific measurements, so the process can compensate for incomplete mechanistic understanding. It can also reveal epistatic combinations that a simple single-mutation model would miss.
When to add AI design early
Bring computational design into the first planning cycle when one or more of these constraints dominates:
Recommended Free Tools
- Screening capacity is the bottleneck. If the laboratory can test only a small fraction of a plausible library, model-based prioritization can concentrate effort on candidates with distinct sequence or structural hypotheses.
- You have enough data to support a model. Useful inputs may include curated homologous sequences, a resolved or predicted structure, substrate-complex information, or internally generated assay data. Poorly curated data can produce confident but misleading rankings.
- You need a focused library. AI can select combinations of substitutions or representatives from sequence space instead of relying only on random mutagenesis.
- You need to move beyond close natural homologues. De novo or distant-homologue design can expand the starting set when known enzymes lack the required substrate scope or operating profile.
- Structural hypotheses could change the search. Models may help prioritize active-site geometry, pocket volume, flexibility, interfaces or stability features for experimental testing.
- You can tolerate a higher validation risk. Computational designs can be generated faster than a laboratory can synthesize and test them, so the program must reserve resources for failures and confirmation.
Do not use a model merely because it produces many sequences. The useful question is whether its ranking is better than the project’s existing baseline, such as random mutagenesis, homolog selection or expert-designed substitutions, when evaluated on the same assay and controls.
What the current evidence says about AI success
A 2024 Current Opinion in Structural Biology review reports that state-of-the-art design protocols can achieve experimental success rates nearing 20%. That is a task-specific, review-level aggregate, not a universal probability that an AI-designed drug-discovery enzyme will work. “Success” can mean different things across studies, including expression, folding, binding or a defined activity threshold.
Rank #3
A separate 2024 review in Nature Reviews Molecular Cell Biology states that de novo design remains limited mostly to α-helix bundles. The limitation matters because many useful enzymes depend on complex folds, conformational changes, long-range communication, metal coordination or regulation. A sequence that looks plausible to a model may still fail to adopt the required active conformation or may express in an unusable form.
These observations support a narrow claim: AI is increasingly useful for proposing and prioritizing experimental candidates. They do not support the broader claim that de novo design has overtaken directed evolution for enzyme drug discovery. Published comparisons use different proteins, assays, library sizes and success definitions, so direct numerical ranking is unsafe.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Repair Windows errors before they cause bigger problems3Fix the driver behind crashes, sound loss and screen glitchesA practical hybrid design-build-test-learn workflow
A hybrid program keeps the assay and the decision endpoint in control while using computation to make each experimental round more informative.
- Define the assay and constraints first. Specify substrate concentration, cofactors, solvent, pH, temperature, format, throughput and acceptance thresholds. Decide which properties are hard requirements and which are optimization goals. Include selectivity and developability criteria rather than treating catalytic activity as the only endpoint.
- Establish a baseline scaffold and controls. Measure the starting enzyme in the intended assay, include inactive and known-active controls where available, and record expression, solubility and stability. Without a baseline, an apparent improvement may reflect assay drift or expression changes.
- Assemble and curate input data. Remove contradictory annotations, distinguish measured activity from prediction, and document sequence identity, assay conditions and structure confidence. If the data are sparse, use the model to generate hypotheses rather than to make high-confidence claims.
- Propose or rank a tractable library. Combine model scores with structural plausibility, sequence diversity and project constraints. Avoid selecting only the top-scoring near-duplicates; reserve part of the library for diverse candidates and controls that test whether the model generalizes.
- Synthesize and test a diverse subset. Use the same assay conditions for all candidates and track failures to clone, express, purify or measure. A non-expressed design is a program result, not simply missing data.
- Feed measurements into the next round. Update rankings or choose the next mutational neighborhood using observed activity, selectivity, stability and expression. Directed-evolution rounds can operate on the best experimental parents while the model proposes combinations that are not obvious from single-mutation effects.
- Confirm hits with orthogonal tests. Re-test independently prepared protein, verify concentration and kinetics, and use a second assay format when feasible. Then examine off-target activity, aggregation, stability, manufacturability and other drug-discovery developability properties before committing to a lead.
The loop should have a stopping rule. For example, stop a design branch when repeated rounds fail to improve the full acceptance panel, when expression remains incompatible with the intended format, or when a simpler scaffold meets the program’s requirements.
Rank #4
How to compare programs fairly
Use the same definitions for both approaches. A fair comparison records at least:
- Experimental hit rate: the fraction of synthesized variants that cross a predeclared activity threshold under the specified assay conditions.
- Qualified-hit rate: the fraction that also meets selectivity, stability, expression and solubility requirements.
- Information gained per variant: whether each test distinguishes a mechanistic hypothesis, a sequence neighborhood or a developability trade-off.
- Time to a reproducible lead: measured from project start to confirmation with independently prepared material, not to the first screening signal.
- Resource use: DNA synthesis, cloning, expression, purification, assay labor, compute and failed-candidate handling.
- Transferability: whether performance survives changes in substrate concentration, matrix, scale or formulation relevant to the intended application.
There is no standardized head-to-head cost, calendar-time or clinical-success statistic for AI-designed enzymes versus directed evolution in the reviewed literature. Treat any projected savings or speedup as a project hypothesis and test it with pilot data. A smaller AI library can still be slower overall if many candidates fail expression or require extensive troubleshooting; a large evolution campaign can be efficient when the assay is exceptionally fast and cheap.
Common failure modes and how to handle them
AI designs score well but show no activity
This often indicates that sequence plausibility or folding confidence was mistaken for catalytic competence. Check whether the model saw comparable active-site geometries and substrate contexts. Expand experimental diversity, include known active controls, and separate expression and folding failures from true catalytic failures.
The model works on familiar sequences but fails on novel ones
That pattern is consistent with out-of-distribution risk. Use novelty as a deliberate experimental variable rather than selecting only the most distant sequences. Blend close homologues, intermediate-divergence candidates and de novo proposals so that the assay reveals how performance changes with distance.
Best Value
Directed evolution produces no improvement
Review library design, mutation load, parent choice and assay dynamic range. Excessive mutation can destroy folding; overly conservative libraries may not reach useful epistasis. Confirm that the screen measures the desired chemistry and that beneficial variants are not lost through expression or growth effects.
Screening becomes the program bottleneck
Reduce the next library using measured sequence-activity relationships, not arbitrary cuts in library size. Pool variants only when the assay can deconvolute positives, and prioritize measurements that distinguish competing hypotheses. AI is most valuable here when it reduces redundant tests without eliminating diverse candidates.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →A hit has activity but poor developability
Do not postpone stability, solubility, expression and selectivity checks until the final candidate. Add them as secondary gates in each round. Catalytic improvement that creates aggregation, rapid degradation or unacceptable off-target activity may not be progress toward a drug-discovery lead.
Decision guide by project starting point
| Project situation | Recommended first move | Reason |
|---|---|---|
| Functional enzyme, fast validated assay, substantial screening capacity | Directed evolution, with computational analysis to design later rounds | Experimental selection can exploit the reliable phenotype immediately. |
| Functional enzyme, slow or expensive assay | AI-prioritized focused library plus a small evolution campaign | Reduce redundant tests while retaining experimental confirmation. |
| No useful scaffold, but strong sequence or structure data | AI-assisted scaffold and homolog exploration, followed by experimental screening | Computation can widen the starting set, but activity remains unproven until tested. |
| Complex fold or strong conformational regulation | Start from experimentally active scaffolds; use AI as a hypothesis and ranking tool | De novo design is less established for complex structural and regulatory behavior. |
| Requirement for unusual substrate scope or extreme operating conditions | Hybrid search across distant homologues, model-guided designs and directed evolution | No single search strategy reliably covers novelty, function and adaptation. |
Questions to settle before committing resources
- What exact reaction and substrate must the enzyme perform, and what assay readout measures it directly?
- What is the minimum acceptable activity, selectivity, stability and expression level?
- How many variants can the laboratory synthesize, express and test per week under the actual workflow?
- Which sequence, structure and assay data are trustworthy enough to inform a model?
- How much sequence novelty is genuinely required, and what validation failure rate can the program absorb?
- Which controls will distinguish catalytic failure from poor expression, aggregation or assay interference?
- At what point will the program switch from model-guided design to broader evolution, or stop a branch entirely?
The decision
Use directed evolution as the default when a validated phenotype and a workable scaffold already exist. Use AI design to narrow the search, propose combinations, explore distant sequence space or supply new starting points when screening capacity or scaffold quality is limiting. For most serious drug-discovery programs, the strongest plan is not AI versus evolution but a measured hybrid: define the assay, let computation focus a diverse library, test real proteins, and let the resulting data determine the next round.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
